Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00302627 · ClinicalTrials.gov registry record · NA
Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation
A NA study, sponsored by Providence Health & Services.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00302627: Completed NA study, sponsored by Providence Health & Services.
NCT00302627 is a NA study that has completed, run by Providence Health & Services. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00302627, a NA study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
Bone is lost rapidly and fractures occur in 10-20% of patients who receive organ transplants within 2 years. The purpose of this study is to evaluate long-term effects of a pamidronate-vitamin D-calcium regimen on bone loss, fractures, and safety in recipients of kidney and heart transplants.
Primary Outcome
Performed at 1 year and 2 years.
Interventions
- DRUG Pamidronate
- DRUG Calcium Carbonate
- DRUG vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1999-01 |
| Est. Completion | 2002-11 |
| Phase | NA |
What the finished NCT00302627 record still lists
NCT00302627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Pamidronate is the first listed.
NCT00302627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00302627 about?
NCT00302627 is a clinical study titled "Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation". Bone is lost rapidly and fractures occur in 10-20% of patients who receive organ transplants within 2 years. The purpose of this study is to evaluate long-term effects of a pamidronate-vitamin D-calcium regimen on bone loss, fractures, and safety in recipients of kidney and heart transplants.
What is the current status of trial NCT00302627?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 1999-01. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00302627?
The interventions under investigation include: Pamidronate (DRUG), Calcium Carbonate (DRUG), vitamin D (DRUG).
Who is sponsoring clinical trial NCT00302627?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00302627's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia